These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Effectiveness of quinolones against Y. pestis]. Kalininskiĭ VB; Vasil'ev NT; Iudin SM Antibiot Khimioter; 1989 Jul; 34(7):521-3. PubMed ID: 2818084 [No Abstract] [Full Text] [Related]
43. [Effect of antibacterial therapy on the epidemic threat of experimental pneumonic plague in monkeys]. Romanov VE; Vasil'ev NT; Shabalin BA; Mironin AV Antibiot Khimioter; 2001; 46(4):16-8. PubMed ID: 11550501 [TBL] [Abstract][Full Text] [Related]
44. Enrichment of Yersinia pestis from blood cultures enables rapid antimicrobial susceptibility determination by flow cytometry. Steinberger-Levy I; Zahavy E; Cohen S; Flashner Y; Mamroud E; Aftalion M; Gur D; Ber R Adv Exp Med Biol; 2007; 603():339-50. PubMed ID: 17966430 [TBL] [Abstract][Full Text] [Related]
45. [Beta-lactam antibiotics (ampicillin, cefotaxime) in prevention of experimental plague in albino mice, caused by non-fractioned strains of the pathogen]. Samokhodkina ED; Ryzhko IV; Tsuraeva RI; Pasiukov VV Antibiot Khimioter; 1994 Jul; 39(7):20-3. PubMed ID: 7840704 [TBL] [Abstract][Full Text] [Related]
46. [Chromosomal resistance of plague agent to quinolones]. Kasatkina IV; Shcherbaniuk AI; Makarovskaia LN; Padeĭskaia EN Antibiot Khimioter; 1991 Aug; 36(8):35-7. PubMed ID: 1661573 [TBL] [Abstract][Full Text] [Related]
47. Antibiotic treatment of experimental pneumonic plague in mice. Byrne WR; Welkos SL; Pitt ML; Davis KJ; Brueckner RP; Ezzell JW; Nelson GO; Vaccaro JR; Battersby LC; Friedlander AM Antimicrob Agents Chemother; 1998 Mar; 42(3):675-81. PubMed ID: 9517950 [TBL] [Abstract][Full Text] [Related]
48. An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. Randremanana RV; Raberahona M; Randria MJD; Rajerison M; Andrianaivoarimanana V; Legrand A; Rasoanaivo TF; Randriamparany R; Mayouya-Gamana T; Mangahasimbola R; Bourner J; Salam A; Gillesen A; Edwards T; Schoenhals M; Baril L; Horby P; Olliaro P Trials; 2020 Aug; 21(1):722. PubMed ID: 32807214 [TBL] [Abstract][Full Text] [Related]
49. Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection. Barnes KB; Richards MI; Laws TR; Núñez A; Thwaite JE; Bentley C; Harding SV Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753342 [TBL] [Abstract][Full Text] [Related]
50. [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen]. Samokhodkina ED; Shcherbaniuk AI; Ryzhko IV; Tsuraeva RI; Skalyga EIu Antibiot Khimioter; 2002; 47(3):26-9. PubMed ID: 16127904 [TBL] [Abstract][Full Text] [Related]
52. Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. Campbell JL; Fay MP; Lanning LL; Hewitt JA Clin Infect Dis; 2020 May; 70(70 Suppl 1):S60-S65. PubMed ID: 32435805 [TBL] [Abstract][Full Text] [Related]
53. Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Louie A; Vanscoy B; Liu W; Kulawy R; Brown D; Heine HS; Drusano GL Antimicrob Agents Chemother; 2011 Jun; 55(6):2623-8. PubMed ID: 21486959 [TBL] [Abstract][Full Text] [Related]
54. [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe]. Shcherbaniuk AI; Liukshina EIu; Ryzhko IV; Smorodinova IuV Antibiot Khimioter; 2006; 51(1):7-10. PubMed ID: 16734358 [TBL] [Abstract][Full Text] [Related]
55. In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens. Halasohoris SA; Scarff JM; Pysz LM; Lembirik S; Lemmon MM; Biek D; Hannah B; Zumbrun SD; Panchal RG J Antibiot (Tokyo); 2021 Dec; 74(12):884-892. PubMed ID: 34522025 [TBL] [Abstract][Full Text] [Related]
56. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. Godfred-Cato S; Cooley KM; Fleck-Derderian S; Becksted HA; Russell Z; Meaney-Delman D; Mead PS; Nelson CA Clin Infect Dis; 2020 May; 70(70 Suppl 1):S11-S19. PubMed ID: 32435800 [TBL] [Abstract][Full Text] [Related]
57. [The experimental validation of the advantages of combined emergency (fluoroquinolones) and specific (EV Nalr) prevention of plague versus their sequential use]. Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Shcherbaniuk AI; Mishan'kin BN; Koroleva NS; Anisimov BN Antibiot Khimioter; 2000; 45(7):10-3. PubMed ID: 10987101 [TBL] [Abstract][Full Text] [Related]
58. [Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe]. Smorodinova IuV; Shcherbaniuk AI; Ryzhko IV; Moldavan IA Antibiot Khimioter; 2005; 50(8-9):23-6. PubMed ID: 17016907 [TBL] [Abstract][Full Text] [Related]
59. [In vitro influence of biologically active factors of microorganisms on antibiotic susceptibility of Yersinia pestis]. Zurabyan VA; Pavlovich NV; Makarovskaya LN; Ryzhkova VV; Bugaeva OK Antibiot Khimioter; 1997; 42(11):22-5. PubMed ID: 9463297 [TBL] [Abstract][Full Text] [Related]
60. Systemic exposure, tissue distribution, and disease evolution of a high solubility ciprofloxacin-aluminum complex in a murine model of septicemia induced by salmonella enterica serotype Enteritidis. Breda SA; Guzmán ML; Confalonieri A; González C; Sparo M; Manzo RH; Bruni SS; Olivera ME Mol Pharm; 2013 Feb; 10(2):598-605. PubMed ID: 23273286 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]